21 Jul / 21
VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering
14 Jun / 21
- AbSci's approach to drug creation has the potential to disrupt conventional biologic drug discovery - Complementary technologies combined to enable streamlined design and production of next-generation therapeutic proteins for disease-specific targets VANCOUVER, Wash., June 14, 2021 /PRNewswire/
22 Feb / 21
VANCOUVER, Wash., Feb. 22, 2021 /PRNewswire/ -- AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI) and potential discovery collaborations with
07 Jan / 21
VANCOUVER, Wash., Jan. 7, 2021 /PRNewswire/ -- AbSci, a leading synthetic biology company enabling drug discovery and biomanufacturing of next generation biotherapeutics, today announced that Sean McClain, Founder and CEO, will present virtually at the 39th Annual J.P.